Evaluation of the Effect of Topiroxostat on Renal Function in Patients with Hyperuricemia: STOP-C Study, a Retrospective Observational Cohort Study.

BACKGROUND: Serum uric acid-lowering therapy is associated with maintaining renal function.
OBJECTIVE: We aimed to retrospectively evaluate renal function and serum uric acid in patients with hyperuricemia who received topiroxostat for over a year.
METHODS: Medical records of patients from 1 January, 2015 to 31 October, 2019 in our hospital were used. From the medical records, data of 100 patients with hyperuricemia treated with topiroxostat were extracted (67:33 male:female). The primary endpoints were changes in serum creatinine level and estimated glomerular filtration rate at 12 months after topiroxostat administration. The secondary endpoints were changes in serum creatinine, serum uric acid, and estimated glomerular filtration rate before and after topiroxostat administration.
RESULTS: The study mainly involved elderly individuals (77.2 ± 9.5 years). Forty-four patients administered uric acid-lowering drugs were switched to topiroxostat. After 12 months, the serum creatinine level and estimated glomerular filtration rate showed no significant changes from baseline; however, the serum uric acid level significantly decreased. The estimated glomerular filtration rate significantly decreased during the 6 months before topiroxostat administration (p < 0.001), but showed no significant change at 6 months after topiroxostat administration (p = 0.849).
CONCLUSIONS: This study revealed that topiroxostat use not only reduced the serum uric acid level but also maintained renal function in elderly patients with hyperuricemia in daily clinical practice.

Key Points

Introduction

Increased uric acid (UA) levels in the blood or hyperuricemia is defined as > 7.0 mg/dL in Japan, causes gouty arthritis and gouty tophus, as urate crystallizes due to low solubility in water [1]. However, hyperuricemia is not only associated with gout but also with a variety of cardiometabolic diseases, including hypertension, chronic kidney disease (CKD), hypertriglyceridemia, obesity, atherosclerotic heart disease, and metabolic syndromes [2-4].

Changes in the UA levels can result in multiple physiological effects that can impair renal function [5]. Previous epidemiological studies involving the general population have shown an independent effect of hyperuricemia on the risk of renal outcomes [6-10].

An association with CKD has been previously reported in patients with asymptomatic hyperuricemia [11]. According to the Japanese guidelines, the treatment of hyperuricemic patients with CKD requires a strict control of the UA level [12], as high UA levels and impaired renal function are interrelated, exacerbating each other. Elderly patients with hyperuricemia are often encountered in clinical practice, and these patients generally have decreased renal function at the start of treatment [7, 13, 14].

Meta-analyses with xanthine oxidoreductase (XOR) inhibitors, such as allopurinol and febuxostat, have shown that UA-lowering treatment in CKD may inhibit the progression of renal function decline [6, 15]. However, it is necessary to reduce the dose of allopurinol in patients with impaired renal function due to the accumulation of allopurinol metabolites [12]. The use of febuxostat in hyperuricemic patients with comorbid cardiovascular disease is controversial owing to concerns of cardiovascular safety [16]. Topiroxostat, a novel nonpurine XOR inhibitor developed in Japan, has been reported to significantly reduce the urinary albumin/creatinine ratio in patients with hyperuricemia associated with renal impairment without changing dosage [17, 18]. One of the merits of topiroxostat is that there is no need to consider topiroxostat dose adjustment depending on renal function.

We have often found that hyperuricemic patients treated with topiroxostat showed improved or maintained estimated glomerular filtration rate (eGFR) and serum creatinine (sCr) levels, along with a reduction in serum UA (sUA). Although some studies have examined the relationship between XOR inhibitors and renal function in clinical practice, few studies have focused on the relationship between sCr and UA-lowering therapy. We conducted a retrospective Study of TOPiroxostat on serum Creatinine levels in patients with hyperuricemia (STOP-C) to investigate the effects of topiroxostat administration on renal function in hyperuricemic patients with impaired renal function in a real-world setting.

Methods

Study Design and Patient Population

The STOP-C study was a single-center, open, retrospective cohort study conducted at Koto Hospital. We assessed the clinical data extracted from the medical records from 1 January, 2015 to 31 October, 2019. The inclusion criteria for data extraction were as follows: (1) patients taking topiroxostat for at least 1 year and (2) patients aged 20 years or older on the first day of administration with topiroxostat. Patients who had the following conditions at the start of treatment with topiroxostat were excluded: (1) serious liver or kidney disease; (2) hemodialysis or kidney transplantation; and (3) a concurrent malignant tumor. The following patients were also excluded: (4) patients taking other UA-lowering drugs additionally to topiroxostat. Topiroxostat was administered considering the patient’s clinical course, without particular limitations.

The study was approved by the Ethics Committee of Koto Hospital in November 2019. In conducting the study, the “Ethical Guidelines for Medical Research Involving Human Subjects” were observed. The information obtained in this study was anonymized and treated with caution to protect the confidentiality of personal information.

Evaluation Parameters

Baseline was considered the first day of topiroxostat treatment. We collected baseline information, including age, sex, and concomitant diseases (hypertension, dyslipidemia, type 2 diabetes mellitus, CKD, atrial fibrillation, and cardiovascular disease), and laboratory parameters, including aspartate transaminase, alanine transaminase, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, glycated hemoglobin, N-terminal pro-brain natriuretic peptide, C-reactive protein, blood urea nitrogen, sCr, sUA, and urinary protein. Serum creatinine and sUA levels in patients who visited the hospital 6 months before baseline only after 1 January, 2015 were also collected. If there was no height record at baseline, the height closest to the baseline was supplemented during the 36 months from baseline. Body weight at baseline and 3, 6, 9, 12, 24, and 36 months from baseline, daily dose of topiroxostat, and concomitant use of other medications for hypertension, type 2 diabetes, or dyslipidemia were also investigated.

Body mass index was calculated by dividing body weight (kg) by height (m) squared. Estimated glomerular filtration rate was calculated using the following equation: eGFR (mL/min/1.73 m2) = 194 × sCr1.094 × age− 0.287 [× 0.739 in the case of women] [19].

Study Endpoints

The primary endpoints were changes in sCr and eGFR from the baseline to 12 months. The secondary endpoints were changes in sCr, eGFR, and sUA at each timepoint after baseline. The exploratory endpoints were considered as the achievement rate of sUA ≤ 6.0 mg/dL at 6 months after the administration of topiroxostat. Changes in eGFR 6 months before and after baseline were also compared as the degree of progression of renal dysfunction.

As an evaluation of safety, adverse events from patient medical information for which a relationship to topiroxostat could not be ruled out were investigated as adverse drug reactions. Additionally, changes in the levels of aspartate transaminase, alanine transaminase, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, glycated hemoglobin, N-terminal pro-brain natriuretic peptide, C-reactive protein, and blood urea nitrogen after administration of topiroxostat were evaluated with an eye towards safety of the patient.

Statistical Analysis

The target sample size was not designed because it was a single-center retrospective observational study; however, the number of patients who could be accumulated in our hospital was estimated to be at least 100. Statistical analysis was performed using SAS version 9.2 (SAS Institute Japan Ltd., Tokyo, Japan). Continuous variables with a normal distribution were expressed as the mean ± standard deviation, and data with a non-normal distribution were expressed as the median and a four-quartile range. The differences in continuous variables were expressed as mean ± standard error. Changes in clinical examination values between the baseline and post-baseline periods for the primary and secondary endpoints were compared using an independent sample t-test for normal distribution values and a nonparametric Mann–Whitney U test for non-normally distributed values. In all statistical analyses, two-sided p values of < 0.05 were considered statistically significant without considering multiplicity. Changes in eGFR between baseline and 6 months after treatment with topiroxostat or between 6 months before baseline and baseline were compared using an independent sample t test.

Results

Patient Background

A total of 104 patients were enrolled in the study. Of these, four patients were excluded from the analysis because of duplicate entries, violation of exclusion criteria 3 or 4, or failure to meet inclusion criteria 1. A total of 100 patients were included in the analysis, and their backgrounds are presented in Table 1. No special restrictions were placed on topiroxostat use; however, patients included in the analysis were markedly elderly, with an average age of 77.2 ± 9.5 years (50–95 years). The prevalence of complications included 95% hypertension, 73% CKD, and 46% atrial fibrillation. Estimated glomerular filtration rate over CKD stage 3 (< 60 mL/min/1.73 m2) accounted for 84% of patients. Other UA-lowering drugs were administered in 44 patients (44.0%) before topiroxostat treatment: allopurinol in 30 patients (mean dose, 108.3 ± 32.4 mg), febuxostat in 12 patients (16.7 ± 11.5 mg), and benzbromarone in two patients (50.0 mg); in 56 patients (56.0%), hyperuricemia was untreated at baseline.

Table 1

Patient backgrounds

Parameter	N = 100	(%)
Male	67	(67.0)
Age (years), mean ± SD	77.2 ± 9.5
≥ 50 and <75	34	(34.0)
≥ 75 and <96	66	(66.0)
BMI (kg/m2), mean ± SD	24.1 ± 4.5
Hypertension	95	(95.0)
Dyslipidemia	87	(87.0)
Type 2 diabetes mellitus	47	(47.0)
Chronic kidney disease	73	(73.0)
Atrial fibrillation	46	(46.0)
Cardiovascular disease	56	(56.0)
Serum creatinine (mg/dL), mean ± SD	1.15 ± 0.27
eGFR (mL/min/1.73 m2), mean ± SD	46.8 ± 15.3
CKD stage
G1	2	(2.0)
G2	14	(14.0)
G3a	31	(31.0)
G3b	46	(46.0)
G4	7	(7.0)
Serum uric acid (mg/dL), mean ± SD	7.01 ± 1.58
BUN (mg/dL), mean ± SD	20.8 ± 6.6

CKD stage: eGFR ≥ 90 in G1, < 90 to ≥ 60 in G2, < 60 to ≥ 45 in G3a, < 45 to ≥ 30 in G3b, < 30 to ≥ 15 in G4

CKD stages were in accordance with the 2012 KDIGO guidelines (Levin A, Stevens PE. Summary of KDIGO 2012 CKD guidelines: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85:49–61.)

BMI body mass index, BUN blood urea nitrogen, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, SD standard deviation

All patients received topiroxostat for up to 12 months, and 51 patients received topiroxostat for up to 36 months. The daily dose of topiroxostat was 50.0 ± 18.3 mg at baseline but increased to 74.4 ± 35.1 mg at 6 months and 90.4 ± 41.0 mg at 12 months, and was maintained at 101.9 ± 48.1 mg at 24 months and 105.5 ± 48.0 mg at 36 months.

Changes in sCr and eGFR

Serum creatinine decreased slightly in all patients, from 1.15 ± 0.27 mg/dL at baseline to 1.14 ± 0.29 mg/dL at 12 months, without a significant change (p = 0.653, Fig. 1A), and eGFR in all patients slightly but not significantly increased from 46.8 ± 15.3 mL/min/1.73 m2 at baseline to 47.1 ± 15.9 mL/min/1.73 m2 at 12 months (p = 0.474, Fig. 1B). The maintenance effect of topiroxostat on renal function was also observed in patients aged over 75 years as well as in patients aged under 75 years (Fig. 1A, B). The eGFR for 12 months was also maintained at each CKD stage (Table 2).

Fig. 1

Changes in serum creatinine (A) and estimated glomerular filtration rate [eGFR] (B) before and after 12 months of topiroxostat administration. Open circle, open square, and closed square indicate “all patients”, “patients over 75 years old”, and “patients under 75 years old”, respectively. Mean ± standard deviation

Table 2

Change in estimated glomerular filtration rate based on CKD stages before and after administration of topiroxostat

CKD stage	Baseline	12 months	p value
G1/G2 (n = 16)	74.2 ± 12.3	70.9 ± 13.4	0.333
G3a (n = 31)	50.8 ±  14.1	52.1 ± 19.0	0.371
G3b (n = 46)	37.8 ± 14.5	39.2 ± 17.6	0.173
G4 (n = 7)	25.0 ± 13.4	26.4 ± 15.5	0.538

Unit is mL/min/1.73 m2; mean ± standard deviation

CKD chronic kidney disease

For 82 patients in whom sCr levels were measured 6 months before baseline, at baseline, and at 6 months after treatment with topiroxostat, the change in eGFR from 6 months before topiroxostat administration significantly decreased by 3.45 ± 0.72 mL/min/1.73 m2 (p < 0.001) from 50.74 ± 15.74 mL/min/1.73 m2, but the change in eGFR after topiroxostat administration was a nonsignificant decrease of 0.18 ± 0.94 mL/min/1.73 m2 from 47.29 ± 15.82 mL/min/1.73 m2 (p = 0.849, Fig. 2A), and the decline of eGFR after topiroxostat administration was suppressed (p = 0.005, Fig. 2B).

Fig. 2

Changes in estimated glomerular filtration rate (eGFR) before and after 6 months of topiroxostat treatment (A) and differences between the two timepoints (B). Changes over time are expressed as the mean ± standard deviation, and differences are expressed as mean ± standard error. M months

Change in sUA

The changes in sUA levels are shown in Fig. 3 and Table 3. The sUA level was significantly decreased by the administration of topiroxostat, and the decrease in sUA level was maintained even after 36 months (Fig. 3).

Fig. 3

Changes in serum uric acid level in response to treatment with topiroxostat. Each timepoint was compared to the baseline. Figures in parentheses indicate the number of patients. Mean ± standard deviation. M months, **p < 0.001

Table 3

Changes in laboratory parameters at baseline and after each timepoint

	Baseline	3 months	6 months	9 months	12 months	24 months	36 months
AST (IU/L)	26.0 ± 9.5 (n = 100)	24.8 ± 9.4 (n = 99)	25.5 ± 9.6 (n = 98)	26.4 ± 12.7 (n = 95)	26.5 ± 10.9 (n = 100)	26.3 ± 9.0 (n = 83)	26.0 ± 9.0 (n = 51)
ALT (IU/L)	19.9 ± 11.0 (n = 100)	19.9 ± 11.2 (n = 99)	19.8 ± 10.2 (n = 98)	19.9 ± 11.3 (n = 95)	20.2 ± 12.7 (n = 100)	20.0 ± 11.2 (n = 83)	18.8 ± 9.3 (n = 51)
HDL-C (mg/dL)	52.3 ± 13.7 (n = 99)	53.0 ± 13.5 (n = 98)	54.6 ± 15.1 (n = 97)	53.6 ± 14.0 (n = 94)	53.7 ± 13.6 (n = 97)	52.8 ± 15.0 (n = 80)	54.5 ± 16.1 (n = 51)
LDL-C (mg/dL)	96.6 ± 33.2 (n = 95)	92.6 ± 27.3 (n = 95)	89.8 ± 28.1 (n = 94)	90.7 ± 28.0 (n = 91)	99.7 ± 105.9 (n = 97)	86.8 ± 27.9 (n = 79)	87.2 ± 26.5 (n = 51)
Triglyceride (mg/dL)	145.6 ± 85.3 (n = 99)	142.3 ± 79.9 (n = 98)	133.8 ± 70.3 (n = 97)	140.5 ± 72.9 (n = 94)	132.9 ± 100.2 (n = 99)	129.7 ± 69.1 (n = 80)	122.9 ± 58.7 (n = 51)
HbA1c (%)	6.13 ± 0.65 (n = 99)	6.11 ± 0.63 (n = 98)	6.12 ± 0.61 (n = 97)	6.26 ± 1.19 (n = 93)	6.13 ± 0.65 (n = 99)	6.12 ± 0.64 (n = 79)	6.11 ± 0.59 (n = 51)
BUN (mg/dL)	20.8 ± 6.6 (n = 100)	21.0 ± 8.3 (n = 99)	21.1 ± 7.8 (n = 98)	21.8 ± 8.9 (n = 94)	21.2 ± 8.7 (n = 100)	21.0 ± 7.6 (n = 83)	22.1 ± 11.1 (n = 51)
Serum creatinine (mg/dL)	1.15 ± 0.27 (n = 100)	1.15 ± 0.31 (n = 99)	1.16 ± 0.30 (n = 98)	1.16 ± 0.37 (n = 95)	1.14 ± 0.29 (n = 100)	1.20 ± 0.34 (n = 83)	1.22 ± 0.53 (n = 51)
eGFR (mL/min/1.73 m2)	46.8 ± 15.3 (n = 100)	46.9 ± 14.6 (n = 99)	46.7 ± 15.6 (n = 98)	47.0 ± 15.3 (n = 95)	47.1 ± 15.9 (n = 100)	45.9 ± 14.1 (n = 83)	47.3 ± 14.5 (n = 51)
Serum uric acid (mg/dL)	7.01 ± 1.58 (n = 99)	5.55 ± 1.49 (n = 99)	5.44 ± 1.65 (n = 98)	5.27 ± 1.72 (n = 95)	5.08 ± 1.56 (n = 99)	4.84 ± 1.55 (n = 82)	4.80 ± 1.57 (n = 51)
NT-proBNP (pg/mL)	347.7 [117.8–917.5] (n = 79)	441.0 [169.2–920.5] (n = 79)	437.1 [163.1–1008.0] (n = 80)	376.6 [121.9–858.2] (n = 79)	412.3 [128.3–870.8] (n = 85)	322.9 [105.3–1115.9] (n = 75)	322.0 [135.0–628.0] (n = 49)
CRP (mg/dL)	0.11 [0.08–0.27] (n = 79)	0.14 [0.07–0.23] (n = 84)	0.12 [0.06–0.26] (n = 85)	0.14 [0.07–0.35] (n = 82)	0.12 [0.07–0.27] (n = 88)	0.13 [0.07–0.29] (n = 76)	0.12 [0.06–0.22] (n = 49)

ALT alanine transaminase, ASL aspartate transaminase, BUN blood urea nitrogen, CRP C-reactive protein, eGFR estimated glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NT-proBNP N-terminal pro-brain natriuretic peptide

Mean ± standard deviation: median (25–75%)

Among 69 patients with sUA > 6.0 mg/dL at baseline and 12 months after topiroxostat administration, 46 patients (66.7%) had sUA ≤ 6.0 mg/dL. In contrast, among 30 patients whose baseline sUA level was 6.0 mg/dL or less, 26 patients (86.7%) maintained an sUA level of 6.0 mg/dL or less after administration of topiroxostat. Of the 44 patients who had been treated with other UA-lowering drugs before the administration of topiroxostat, 12 months after the administration of topiroxostat, 32 patients (72.7%) had sUA levels of 6.0 mg/dL or less.

Safety

There were no serious adverse events after the administration of topiroxostat. Regarding the laboratory parameters, there were no significant changes in any of the parameters other than sUA after the administration of topiroxostat (Table 3).

Discussion

This study showed that topiroxostat significantly reduced sUA levels in patients with hyperuricemia, who were mainly elderly and associated with impaired renal function. There was no significant increase in sCr levels after treatment with topiroxostat. Furthermore, the eGFR 6 months before the administration of topiroxostat until baseline was significantly decreased, while a decrease in eGFR was not observed after the administration of topiroxostat. These results suggest that topiroxostat has the potential to relieve the decline in renal function over time.

The primary treatment goal in patients with hyperuricemia is to decrease sUA levels and to control the levels to 6.0 mg/dL or less to prevent gout [12]. Recent studies have demonstrated that hyperuricemia is likely to be implicated in the onset and progression of CKD, alongside worsening renal function in various cohorts or community-based populations [10, 20, 21].

Chronic kidney disease progression may lead to end-stage renal disease, which requires renal replacement therapy such as dialysis or kidney transplantation. Chronic kidney disease has also been reported to be associated with higher risks of death from any cause [22], cardiovascular events [23], hospitalization, and higher healthcare costs [24]. Therefore, prevention of CKD development and/or progression is a major public health issue.

It has been reported that individuals with UA levels > 5.9 mg/dL have an increased risk of a decrease in eGFR of 3 mL/min/1.73 m2 per year or greater in a longitudinal analysis [8]. In this study, during the last 6 months before treatment with topiroxostat, sCr slightly increased (0.070 mg/dL), and eGFR decreased by 3.45 mL/min/1.73 m2. These changes were greater than those described above; however, they may be caused in part by the combination of hyperuricemia and risk factors for renal function, such as hypertension, dyslipidemia, and type 2 diabetes. Six months after treatment with topiroxostat, eGFR increased by only 0.18 mL/min/1.73 m2 (sCr increased by only 0.010 mg/dL). Although this is a short-term comparison, it seems reasonable to consider that the decrease in renal function over time was suppressed by the administration of topiroxostat.

In a prospective randomized trial, allopurinol significantly suppressed the reduction in eGFR compared with that in the control group (p = 0.018) [25]. In a meta-analysis of 19 studies with allopurinol, a difference of 3.2 mL/min/1.73 m2 was observed in the reduction of eGFR between patients with G3 or higher CKD and the control group [26]. In the case of febuxostat, a meta-analysis of 11 studies of patients with hyperuricemia associated with CKD showed a significant reduction in sUA [27]. Simultaneously, the eGFR difference with that of the control group was not significant, coming in at 2.36 mL/min/1.73 m2. These results indicate that XOR inhibitors are more effective than conventional therapies in suppressing the decline in renal function. In this study, suppression of declining renal function by topiroxostat administration was also observed in the patient group aged over 75 years.

Although CKD is associated with increased sUA levels, the incidence of hyperuricemia in stages G3b and G4 of CKD is 2.12 and 4.57 times higher than in stage G3a, respectively [14]. The proportion of patients in the optimal range for the sUA level according to the CKD stage (G3a, G3b, G4, and G5) has also been reported in both sexes [14]. In addition, the relationship between decreased eGFR and the risk of end-stage renal disease in patients with CKD in Japan was clearly revealed [28]. In this study, topiroxostat suppressed the decline in renal function in patients with hyperuricemia, about half of whom were switched from other XOR inhibitors. Taken together, topiroxostat may be more beneficial for the treatment of patients with hyperuricemia.

Long-term administration of UA-lowering drugs is required in patients with hyperuricemia; therefore, safety is also an important clinical problem. A total of 100 patients in this study were able to receive topiroxostat for over 12 months, and there were no adverse events or abnormal liver function values for which a causal relationship to topiroxostat could not be ruled out. The long-term (12-month) efficacy and tolerability of topiroxostat have been further confirmed in an observational study conducted in over 4000 patients [29].

This study has some limitations. First, this was a retrospective single-center study, which may introduce selection bias and was evaluated in one ethnic group (Japanese). Second, there were a small number of subjects, as there were not many patients who received topiroxostat for more than 1 year at our hospital, which may limit the strength of our conclusions. However, our data can be considered “real-world” data of daily clinical practice. Third, the treatment period was comparatively short, which may explain why the eGFR did not improve over the time span measured. While some clinical data, including our study, are promising, well-designed large-scale and long-term studies are warranted to evaluate whether topiroxostat improves renal function in patients with hyperuricemia.

Conclusions

This study revealed that topiroxostat treatment not only reduced serum UA levels significantly, but also maintained sCr and eGFR in hyperuricemic patients. Importantly, these findings were obtained from elderly patients for over 1 year. Thus, topiroxostat may be a useful UA-lowering agent for elderly patients with hyperuricemia in daily clinical practice.

Topiroxostat, administered for more than 1 year, did not increase serum creatinine and retained estimated glomerular filtration rate in patients with hyperuricemia up to chronic kidney disease stage G4, including 66% of patients aged ≥ 75 years. The mean serum uric acid decreased significantly within 3 months after topiroxostat administration, reaching ≤ 6.0 mg/dL, as recommended by the guidelines.

The estimated glomerular filtration rate decreased significantly from 6 months before topiroxostat administration to baseline, but the decline in the estimated glomerular filtration rate was suppressed at 6 months after topiroxostat administration.

Topiroxostat may be a useful uric acid-lowering agent for elderly patients with hyperuricemia in daily clinical practice.